Azithromycin Reduces Lung Inflammation in Cystic Fibrosis Mice
Author Information
Author(s): Legssyer Rachida, Huaux François, Lebacq Jean, Delos Monique, Marbaix Etienne, Lebecque Patrick, Lison Dominique, Scholte Bob J, Wallemacq Pierre, Leal Teresinha
Primary Institution: Université Catholique de Louvain
Hypothesis
Azithromycin modulates lung inflammation in cystic fibrosis mice.
Conclusion
Azithromycin reduces some lung inflammation outcome measures in cystic fibrosis mice.
Supporting Evidence
- Azithromycin treatment reduced BALF macrophage numbers in CF mice.
- MPO activity in lung homogenates was significantly reduced after azithromycin treatment.
- Neutrophil infiltration in CF mice was decreased with azithromycin treatment.
- Pro-inflammatory cytokine release was inhibited in LPS-induced inflammation in CF mice treated with azithromycin.
Takeaway
This study found that azithromycin can help reduce inflammation in the lungs of mice with cystic fibrosis, which might help people with the disease.
Methodology
Cystic fibrosis mice were treated with azithromycin for 4 weeks, and their lung inflammation was assessed through various biochemical and cellular analyses.
Limitations
The study was conducted on mice, which may not fully replicate human responses.
Participant Demographics
Young adult female CF mice homozygous for the ΔF508 mutation.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website